New actionable biomarkers are constantly emerging in NSCLC. Many of these biomarkers are currently being investigated and validated in clinical trials and will potentially be implemented in routine testing.
See what thoughts leaders have shared during the "Advances in application of next-generation sequencing in lung cancer biomarker testing in the diagnostics and research setting" symposium. You will learn more about the value of next next-generation sequencing in NSCLC biomarker testing for targeted therapies and new applications in clinical research.
Download what they have presented.
|Part 1 NGS in NSCLC routine biomarker testing for targeted therapies|
Oncologist point of view: Promise and challenge of growing options for NSCLC targeted therapy
With the increasing number of targeted therapies in NSCLC, simultaneous testing for multiple biomarkers is becoming progressively important to ensure a timely diagnosis and start of treatment. Professor Smit will discuss the advantages of existing, new, and emerging targeted therapy; and the importance of timely diagnosis for patients with oncogene-driven NSCLC.
Pathologist view: How to satisfy increasing demand for multiple biomarker testing from limited sample
New targeted treatments give hope to patients, but at the same time, form a challenge to the laboratories that have to deal with the increasing demands for biomarker testing. Especially in NSCLC, as increasing numbers of genomic alterations are found to be clinically relevant and actionable, sequential or parallel testing of individual driver mutations using independent tests (one marker/one test/one drug paradigm) can be a significant resource and time challenge for clinical laboratories and can consume scarce and valuable tumour samples. Dr Quagliata will share his experiences in the comparison and evaluation of multiple biomarker NGS testing vs single-gene methods in NSCLC testing for EGFR, BRAF, KRAs, ROS1, and others, and describe results of optimising and standardising current testing algorithms, including possible pitfalls and practical advice.
Evaluation of NGS and other methods for ALK tranclocation detection in European NSCLC patients - results of the European Thoracic Oncology Platform (ETOP) Lungscape Project
The detection of translocation and fusion biomarkers is of particular importance in NSCLC. Over the years, there has been a lot of discussion about which is the best method – IHC or FISH or a combination of the two. Now, NGS is entering the field, allowing for the detection of multiple fusions as well as mutations in one test, from one sample. How does it correlate with the FISH and IHC? Is it as robust and efficient? Professor Finn will discuss the results of a large study comparing FISH, IHC, PCR, and NGS techniques for ALK translocation/fusion detection in 96 resected NSCLC samples from the large ETOP Lungscape cohort and give his opinion on the NGS case.
|Part 2 New applications of NGS in clinical research|
Circulating tumour DNA testing in NSCLC clinical research: an international consortia study
Liquid biopsy is generating a lot of interest among the laboratory and clinician communities as a technique that not only noninvasively detects relevant solid tumour biomarkers but also has enormous potential for use in future cancer diagnostics and monitoring. Professor Hummel will describe the results of the evaluation of the NGS method in NSCLC biomarker detection. The study was conducted across 11 European centres and established the reproducibility, repeatability, specificity, and sensitivity of the test.
New NSCLC biomarkers in clinical research - detection of MET skipping mutation, EGFR T790M and other important biomarkers
New actionable biomarkers are constantly emerging in NSCLC. Many of these biomarkers are currently being investigated and validated in clinical trials and will potentially be implemented in routine testing. Dr López-Ríos will present his laboratory experience in evaluating NGS for the detection of some of them, like high-level MET amplification, MET exon 14 skipping mutation, EGFR T790 mutation, and other key resistance mutations.